Abstract
Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. While adjuvant (adj) PD1 is used for resected stage III/IV AM and MM, there are no data regarding efficacy in these subgroups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
